Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group (Q78171513)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

title

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference

Reddy KR

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Hoofnagle JH

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Tong MJ

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Lee WM

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Pockros P

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Heathcote EJ

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Albert D

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Joh T

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

language of work or name

English

0 references

publication date

1 September 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

page(s)

787-793

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis C: the clinical spectrum of disease

12 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Therapy of hepatitis C: interferon alfa-2a trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Therapy of hepatitis C: interferon alfa-n1 trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Re-treatment of chronic hepatitis C with consensus interferon .

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Marrow granulocyte reserves in black Americans. Hydrocortisone-induced granulocytosis in the "benign" neutropenia of the black

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

The interferon sensitivity determining region: all hepatitis C virus isolates are not the same

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic re

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Racial differences in health: not just black and white, but shades of gray

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300319

7 January 2021

Identifiers

DOI

10.1002/HEP.510300319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10462387%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference